Overview
Dorea formicigenerans is a strictly anaerobic, Gram-positive bacterium belonging to the family Lachnospiraceae within the phylum Firmicutes. Named for its characteristic production of formate from carbohydrate fermentation, it is a common member of the human gut microbiome. Research indicates that D. formicigenerans has a dual role in gut health: while it contributes to short-chain fatty acid production and colon integrity, elevated levels are consistently associated with obesity, irritable bowel syndrome, and metabolic risk factors.
Classification
D. formicigenerans belongs to the genus Dorea within the Lachnospiraceae family, alongside the closely related species Dorea longicatena. The genus Dorea was established to accommodate certain species previously classified within Eubacterium. Both Dorea species share ecological niches in the gut and are often co-identified in microbiome studies examining metabolic health associations. The Lachnospiraceae family more broadly includes beneficial butyrate producers such as Roseburia intestinalis.
Key Characteristics
D. formicigenerans ferments carbohydrates to produce formate and other SCFAs, contributing to the overall metabolic output of the gut microbial community. Its formate production may serve as a substrate for other microorganisms in cross-feeding networks. However, the species name reflects its primary distinguishing metabolic feature: the generation of formic acid. The type strain ATCC 27755 has been used as a reference in multiple microbiome association studies. The bacterium has been identified in gut-brain axis research, though its specific neuroactive contributions remain under investigation.
Health Significance
The health significance of D. formicigenerans appears to be context-dependent. A cross-sectional study of 128 participants found it significantly elevated in overweight and obese subjects, with positive correlations to anthropometric obesity parameters, BMI, and lipid cardiovascular risk factors. It has also been identified as elevated in IBS patients alongside Ruminococcus and Clostridium, with corresponding reductions in protective species like Faecalibacterium prausnitzii and Bifidobacterium. At normal levels, its formate and SCFA production likely contributes positively to colon integrity. However, its elevation in obesity and inflammatory gut conditions suggests that dose-dependent and context-dependent effects may determine whether its presence is beneficial or indicative of dysbiosis. Monitoring D. formicigenerans levels may serve as a useful biomarker for metabolic and gastrointestinal health assessment.